TG Therapeutics Inc (NASDAQ:TGTX)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - TGTX

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - TGTX

  • Market Cap$3.420bn
  • SymbolNASDAQ:TGTX
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS88322Q1085

Company Profile

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

Latest TGTX news

Currently there for this company. Visit our news hub for other news .